Host Paul Sax, MD, FIDSA, is joined by Libby Hohmann, MD, FIDSA, an ID specialist at Massachusetts General Hospital, director of the Fecal Microbiota Transplant Lab and associate professor of medicine at Harvard Medical School, to discuss the innovative field of microbiome-based therapy, including the latest therapeutics, efficacy in treating COVID-19 and advice on treating patients with C. diff.
The IDSA Leadership Institute empowers infectious diseases and HIV practitioners to be future leaders. Crafted specifically by and for specialists in infectious diseases and HIV, the Leadership Institute offers two tailored leadership development pathways.